Beruzatatug (BNT326/YL202 Antibody) is an IgG1 monoclonal antibody against HER3. Beruzatatug can be used for the synthesis of ADCs, such as BNT326/YL202 [1].
References:
[1]. Cheng Y, et al. YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial.
References:
[1]. Cheng Y, et al. YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial.